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Psychiatric disorders are a diverse set of diseases that affect all aspects of mental function
including social interaction, thinking, feeling, and mood. Although psychiatric disorders
place a large economic burden on society, the drugs available to treat them are often
palliative with variable efﬁcacy and intolerable side-effects. The development of novel
drugs has been hindered by a lack of knowledge about the etiology of these diseases.
It is thus necessary to further investigate psychiatric disorders using a combination of
human molecular genetics, gene-by-environment studies, in vitro pharmacological and
biochemistry experiments, animal models, and investigation of the non-biological basis
of these diseases, such as environmental effects. Many psychiatric disorders, including
autism spectrum disorder, attention-deﬁcit/hyperactivity disorder, mental retardation, and
schizophrenia can be triggered by alterations to neural development. The zebraﬁsh is
a popular model for developmental biology that is increasingly used to study human
disease. Recent work has extended this approach to examine psychiatric disorders as
well. However, since psychiatric disorders affect complex mental functions that might
be human speciﬁc, it is not possible to fully model them in ﬁsh. In this review, I will
propose that the suitability of zebraﬁsh for developmental studies, and the genetic tools
available to manipulate them, provide a powerful model to study the roles of genes that
are linked to psychiatric disorders during neural development. The relative speed and
ease of conducting experiments in zebraﬁsh can be used to address two areas of future
research: the contribution of environmental factors to disease onset, and screening for
novel therapeutic compounds.
Keywords: zebrafish, psychiatric disorders, development, attention-deficit/hyperactivity disorder, autism spectrum
disorder, schizophrenia, mental retardation
INTRODUCTION
Psychiatric disorders are a diverse group of diseases that can
affect all aspects of mental function including thinking, feeling,
mood, and sociability. Psychiatric disorders place a massive strain
on society. They are the leading cause of disability in Europe
and North America (Eaton, 2008) and rank second in the bur-
den of diseases in established market economies (World Health
Organisation [WHO], 2008). However, the drug therapies avail-
able to treat psychiatric diseases are often only palliative and
have variable efﬁcacy and side-effects. Many of the compounds
used to treat psychiatric disorders were discovered serendipitously
more than 50 years ago and have not been signiﬁcantly improved
since (WHO, 2008). Furthermore, the high costs associated with
developing new treatments, estimated at roughly $1.8 billion per
drug, has prompted several major pharmaceutical companies to
reduce or cancel their central nervous system research programs
(Paul et al., 2010). One of the factors that have hindered the
discovery of novel drugs is a lack of knowledge regarding the
genetics and neurobiology of these diseases. Further research into
the etiology of psychiatric disorders, driven by a combination
of human genetic studies and animal models, and taking into
account environmental inﬂuences, is needed in order to improve
drug treatments and develop early prodomic interventions (before
disease symptoms are visible) that could prevent or delay disease
onset.
THE ENVIRONMENTAL AND GENETIC BASIS OF
PSYCHIATRIC DISORDERS
Psychiatric disorders are caused by interaction of multiple factors
that has been described by Gottesman and Gould (2003) as a “bal-
let that is choreographed over time between the action of multiple
genes, environment and epigenetic factors.” Initially, psychiatric
disorders were thought to be triggered by the environment with
only a limited inﬂuence of genes (Cooper, 2001). However, since
the advent of genome-wide association studies (GWAS), there has
been an increase in the amount of work that focuses on the genetic
basis of psychiatric disorders. In parallel, data from twin family
and adoption studies have uncovered heritability estimates for dis-
eases such as schizophrenia (81%), attention-deﬁcit/hyperactivity
disorder (ADHD, 80%), and autism spectrum disorder (ASD, 70–
80%) suggesting a critical role for genetic lesions in these disorders
(Sullivan et al., 2003; Bailey et al., 2005; Rosenberg et al., 2009;
Banaschewski et al., 2010). Since it is difﬁcult to study psychoso-
cial interactions in animal models, this review will concentrate on
the genetics of psychiatric disorders with a focus on alterations to
early neural development.
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The genetics of psychiatric disorders are often complicated,
with a non-Mendelian inheritance pattern and a continuous vari-
ation in phenotype suggesting that they might be caused by the
action of multiple genes. This observation led to the common
disease-common variant (CDCV) hypothesis: inheritance of one
variant alone is not enough to cause a disease, but when combined
with others a theoretical threshold will be passed and the disease
triggered (Mitchell, 2011). As a result of the CDCV hypothesis,
GWAS have been used to identify many genes associated with
psychiatric disorders. GWAS are based upon the principle that
multiple disease-causing variants (such as single nucleotide poly-
morphisms, SNPs) will be maintained in linkage-disequilibrium
and so can be detected in an unbiased manner (Frazer et al.,
2009). However, it is often unclear whether a loss or gain of gene
function leads to expression of a psychiatric disorder. Following
GWAS, mechanistic studies are then needed to show that iden-
tiﬁed variants participate in the disease being studied. Despite
their promise, the contribution of GWAS to the understanding
of psychiatric disorders has not been very impressive (Gottes-
man and Gould, 2003). Genes identiﬁed by GWAS still only
account for a small percentage of the heritability of complex traits
(Frazer et al., 2009) with poor correspondence of data across stud-
ies (Mitchell and Porteus, 2011). This is due to a combination of
the modest effect of causative mutations on disease susceptibility,
under-powered studies with small sample sizes, and the need to
take environmental inﬂuences into account when studying genetic
lesions.
Recent research has provided evidence that some psychiatric
disorders, including schizophrenia, ADHD, autism, and men-
tal retardation can also be triggered by mutations in single
genes [sometimes referred to as the common disease rare vari-
ant (CDRV) hypothesis; Sebat, 2007; Walsh et al., 2008; Elia et al.,
2009; Girirajan andEichler,2010;Williams et al.,2010; Geschwind,
2011; Lesch et al., 2011; Lionel et al., 2011; Veltman and Brunner,
2012]. Studies of families that suffer from psychiatric disorders
often reveal de novo (or private) mutations which are unique to
a given population or family. In fact, current estimates suggest
that on average up to 74 novel mutations may occur per genome
per generation in the non-disease population (Veltman and Brun-
ner, 2012), with psychiatric disease families showing even higher
than normal rates (Girard et al., 2011). These mutations are rare
(comprising less than 1% of the minor allele frequency) and can
either represent SNPs or be contained within copy number vari-
ations (CNVs) – deletions or duplications that can affect one or
more genes at the same time (Sebat et al., 2009). CNVs occur quite
frequently and have a mutation rate that is three to four times
higher than other genomic areas, accounting formore genetic vari-
ation thanother types of polymorphism (Cook andScherer,2008).
Mutations can alter gene function in several ways, each of which
can potentially lead to a psychiatric phenotype: they can activate
proteins, create abnormal biochemical functions, or abrogate gene
activity (Walsh, 1999;Walsh and Engle, 2010). Furthermore, a sin-
gle gene can sometimes be mutated in multiple positions, each
of which can trigger a different disease; whilst psychiatric disor-
ders may be caused by a large number of different mutations, they
might paradoxically only be linked to a small number of genes. For
example, mutations in Disrupted in Schizophrenia 1 (Disc1) can
lead to schizophrenia, bipolar disorder, major depressive disor-
der, and autism (Porteous et al., 2011). Similarly, a microdeletion
at human chromosome locus 22q11 is associated with a range of
diseases including schizophrenia and velocardiofacial syndrome,
anxiety, depression, ADHD, obsessive-compulsive disorder, and
ASDs (Gothelf et al., 2004). Thus, seemingly diverse diseases may
share a common genetic basis, making it possible to identify
disease-causing variants in known – rather than novel genes in
some cases.
The relative contribution of rare or common mutations to dis-
ease susceptibility is not known. Psychiatric disorders could be
caused by a combination of several types of genetic lesion rather
than a single mutation alone (Veltman and Brunner, 2012). Single
mutations might predispose patients to mental illness, while other
SNP polymorphisms in the genetic background (or mutations in
a second critical gene) could alter disease penetrance (Girirajan
and Eichler, 2010; Mitchell and Porteus, 2011). Therefore, a single
mutation may be necessary but not sufﬁcient to trigger the disor-
der. Such a combinedmodel would explain the large heterogeneity
of symptoms and the low penetrance that is sometimes observed.
The potential interaction between rare and common mutations
in the etiology of mental disease is reminiscent of the genetics of
cancer. According to Knudson’s two-hit hypothesis, cancer can be
triggered by the combination of two or more mutations (Knud-
son, 1971). A recessive germline mutated allele is inherited from
one parent, followed by a novel somaticmutation in the same gene
(Guidry and Kent, 1999). The combination of common variants
and rare mutations associated with psychiatric disorders raises the
possibility that psychiatric disorders may also be caused by loss
of heterozygosity or by the inheritance of two “hits” in separate
genes (Girirajan and Eichler, 2010; Toro et al., 2010). The consid-
erable number of brain areas and processes affected by psychiatric
disorders provide a large pool of mutable genes which could lead
to expression of a disease (Xu et al., 2008). As an example of this,
CNVs in both NRXN1 and CNTNAP2 have been linked to Pitt–
Hopkins-like syndrome, a familial disease that includes autistic
symptoms (Zweier et al., 2009). Patients with Pitt–Hopkins-like
syndrome have been found to have lost one copy of NRXN1 or
CNTNAP2 coupled to a deleterious point mutation in the second
allele of the same gene (Toro et al., 2010).
Interestingly, phylogenetic analysis of disease-causing muta-
tions suggests that our current classiﬁcation of psychiatric
disorders may be based upon culturally acceptable behavioral
norms. For example, in the case of the ADHD-linked gene
LATROPHILIN3, the disease-causing variant is ancestral with
protective variants arising over time (Arcos-Burgos et al., 2010;
Domene et al., 2011). Thus some of the symptoms of ADHD –
including hyperactivity and impulsivity – were either advanta-
geous or at least not selected against during evolution. Similar
results have been found for Calretinin polymorphisms linked
to schizophrenia (Farokhashtiani et al., 2011), with disease-
causing variants found in other distantly related vertebrate
species.
The interaction of genes with environmental factors (including
infection, drugs, malnutrition, psychosocial adversity, or obstet-
ric complications) is likely to play a signiﬁcant role in the risk
of suffering from a psychiatric disorder. Genes may predispose
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people to suffer from a disease, which is triggered when an adverse
environment is encountered. Thus the severity of a disease might
be determined by the interaction of a single gene with different
environmental factors. These environmental factors may also be
under genetic control. For example, the genetic variants that cause
maternal ADHD also increase the propensity of mothers to drink
or smoke (Castellanos et al., 1996; Laucht et al., 2007; Thapar et al.,
2009). Furthermore, the number of germline mutations in sperm
increases with age, exacerbating the likelihood of suffering from
psychiatric disorders such as autism (Veltman and Brunner, 2012).
In some cases, environmental inﬂuences may ultimately reﬂect the
interaction of the parent’s and child’s genomes in expression of
mental illness (Castellanos et al., 1996; Laucht et al., 2007). The
gene-by-environment (G × E) interactions that lead to psychi-
atric disorders are poorly understood. However, a recent study of
the human ADHD-risk gene LATROPHILIN3 suggests that G × E
interactions may not have a linear impact upon disease suscep-
tibility (Choudhry et al., 2012). In impoverished environments
(such as maternal stress during pregnancy), mutation of LPHN3
has little contribution to disease onset with environmental factors
playing a major role. However, in adequate or enriched environ-
ments, polymorphisms in LPHN3 have a greater chance to trigger
the disorder (Choudhry et al., 2012).
ALTERATIONS TO EMBRYONIC DEVELOPMENT CAN LEAD TO
PSYCHIATRIC DISORDERS
Many of the rare mutations linked to psychiatric disorders are
found in genes that are active during embryonic development.
Subtle disruptions to the homeostasis of normal development can
have far-reaching consequences that lead to permanent alterations
in the function of the mature brain (Mitchell, 2011). Psychi-
atric disorders can thus be conceptualized as deviations in the
normal trajectory of embryonic development within acceptable
noise levels resulting in non-lethal modiﬁcations of behavior
(West-Eberhard,2005). Genetic variation anddevelopmental plas-
ticity (including chance events) are a fundamental property of
all living organisms and provide the raw material upon which
evolution can act. Development thus constitutes a series of branch-
ing pathways in which developmental decisions switch between
different potential endpoints (West-Eberhard, 2005). For exam-
ple, dopaminergic neurons show a surprisingly stochastic wiring
pattern in larval zebraﬁsh, even though they are thought to be
genetically homogenous (Tay et al., 2011). Extreme alterations
to embryonic development are likely to be lethal. However, if
a mutation coincides with a chance event, a subtle change to
embryonic development that leads to a psychiatric disorder may
occur. Alterations to neural development can act at the cellular or
circuit level. In some cases mutations may cause speciﬁc pheno-
types linked to neurological disorders, such as the control of cell
division, migration, differentiation, and survival, or changes to
neurite outgrowth, axon pathﬁnding, and dendritic architecture
(Thornton and Woods, 2009; Valiente and Marin, 2010). Alterna-
tively, mutations may cause more diffuse and variable alterations
to brain function: miswiring of neural circuits, disinhibition of
local interneurons, or adjustment of normal brain homeostasis
leading to pathophysiology (Lisman et al., 2008), a process which
has been called“developmental disconnection” in relation toASDs
(Geschwind and Levitt, 2007). Diffuse changes to brain function
seem particularly likely to lead to psychiatric diseases when con-
sidering that genes do not directly control behavior, but rather act
via the formation, connection, and function of neural circuits.
TRANSLATIONAL MODELS OF PSYCHIATRIC DISORDERS IN
ZEBRAFISH
Although recent studies have uncoveredmany genes linked to psy-
chiatric disorders, only few of them have been experimentally
validated. Therefore, mechanistic studies are required in order
to investigate whether a loss− or gain−of-function contributes
to disease pathology in each case. The complex genetic basis of
psychiatric disorders makes it difﬁcult to fully recreate them in
animal models. Thus, the challenge of studying these diseases
consists of integrating basic molecular data from animals with
information about complex human mental functions at the cir-
cuit level (Geschwind, 2008). One way to simplify this problem
is to measure endophenotypes, neuropsychological or biological
markers that correlate to a disease-gene’s activity (Gottesman and
Gould, 2003; Kendler and Neale, 2010). An ideal endophenotype
should be controlled by a single gene, be associated with expres-
sion of the disease in the population and be both heritable and
state independent (meaning that it is expressed even when the ill-
ness is not active; Rommelse, 2008). Although in animal models
endophenotypes have rarely fulﬁlled all of these criteria, their use
may simplify the translation of information to human patients.
Furthermore, the division of psychiatric disorders according to
endophenotypes may help reﬁne their diagnosis; diseases could
thus be reclassiﬁed on the basis of their molecular pathology
instead of behavioral or psychological symptoms, providing an
explanation for comorbidity with other disorders (Gottesman and
Gould, 2003).
Despite the difﬁculty of modeling psychiatric disorders, animal
studies still have the potential to give insights into the etiology
of mental illness. The advent of tools to manipulate genes has
now allowed the creation of animal models that are ﬁrmly based
upon the genetic pathways underlying a disease. A perfect ani-
mal model should have three main attributes: construct validity
(meaning that it conforms to the underlying rationale of the dis-
ease), face validity (mimicking some of the characteristics of the
disease), and predictive validity (the ability to accurately predict
outcomes or symptoms in humans; Sarter et al., 1992; Einat et al.,
2003; Arime et al., 2011). The animal model should also combine
genetic tractability, tools to visualize and manipulate neurons in
vivo, and the ability to translate ﬁndings to patients based upon
conserved neurobiology.
Zebraﬁsh have already been established as a powerful model
for developmental biology and neuroscience. Zebraﬁsh develop
rapidly outside of the mother making it easy to collect andmanip-
ulate embryos. By 6 days, larval ﬁsh swim continuously, search
for food, and are able to escape from predators thus demonstrat-
ing a range of behaviors. Zebraﬁsh are transparent until larval
stages allowing the study and manipulation of neural circuits
at the cellular level in the intact brain (Fetcho and Liu, 1998).
Furthermore, a large number of identiﬁed mutant lines, genetic
tools such as TALENs (transcription activator-like effector nucle-
ases) and zinc-ﬁnger nucleases to knock-out genes; Amacher,
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2008; Huang et al., 2011; Sander et al., 2011), genetic ablation
(Curado et al., 2007), optogenetics (Nagel et al., 2003; Zhang et al.,
2007), and techniques to monitor neural activity (including cal-
cium indicators and electrophysiology; Higashijima et al., 2003)
have already been established. Although the formation, position,
and function of neurotransmitter signaling pathways sometimes
differ between zebraﬁsh and other vertebrates, comparative stud-
ies are beginning to precisely map these differences, allowing
the transfer of information gained in zebraﬁsh to other species
(Tropepe and Sive, 2003). Furthermore, a battery of tests for
behavioral analysis of both larval and adult zebraﬁsh has already
been developed (Fero et al., 2011; Norton and Bally-Cuif, 2010;
Norton et al., 2011). Although tools to study neuroscience are
already available in other genetically tractable vertebrates such
as mouse, the ease of generating large numbers of zebraﬁsh and
their transparency make them ideal for high-throughput analy-
ses and imaging studies. As a model for behavioral neuroscience,
the zebraﬁsh is particularly useful for optogenetic dissection of
the behavior, time-lapse analysis of neurotransmitter pathway
formation during development and screening for novel thera-
peutic treatments. For example, the compensatory changes to
neurotransmitter signaling pathways that occur following genetic
manipulation can be examined in zebraﬁsh. Abrogation of a single
gene will most likely lead to the modiﬁcation of multiple neuro-
transmitters. These ﬂuctuations could be examined in two ways.
The levels of neurotransmitters in the brain could be measured
directly by either high pressure liquid chromatography (HPLC) or
an enzyme-linked immunosorbent assay (ELISA). Alternatively,
the alterations to neural circuits in the brain could be uncovered
using calcium indicators driven by neurotransmitter-speciﬁc pro-
moters [such as otpb. A for dopamine (DA; Fujimoto et al., 2011)
or pet1 for serotonin (5-HT; Lillesaar et al., 2009)]. Neural activity
(detected as ﬂashes of calcium signaling) could bemeasured in ﬁsh
lacking a functional copy of an ADHD-linked gene. This informa-
tion might provide clues about the signaling pathways and brain
areas underlying a phenotype and so provide avenues for future
research.
The power of zebraﬁsh to study developmental biology suggests
that it may make important contributions to the study of genes
associated with psychiatric disorders. The zebraﬁsh homologs
of genes linked to psychiatric disorders can be identiﬁed, and
their basic function during neural development (related to neu-
ral circuit formation or behavior for example) analyzed following
manipulation. For example, a zebraﬁsh line could be created
which harbors a mutation mimicking the situation in human
patients. This could include replacing thewild-type zebraﬁsh tran-
script with a humanized form of the gene or knocking the gene
down by TALEN or morpholino injection. The developmental
and behavioral phenotype of the manipulated ﬁsh could then
be characterized. Environmental interactions with these models
could be studied by applying standardized environmental manip-
ulations – for example, by stressing the ﬁsh before testing behavior
(Amir-Zilberstein et al., 2012), growing embryos in a hypoxic envi-
ronment (Marks et al., 2005) or treating with alcohol or nicotine
(see below). The data generated by this approach could then be
veriﬁed in rodents and if similar results are obtained then clinical
trials would be initiated. Apparent behavioral similarities between
animals (which are often used to develop models of human dis-
eases) may not ensure that the same underlying process is being
measured, since each behavior might not serve the same purpose
in all species. In contrast to this, developmental models of psychi-
atric disorders may have improved construct validity if the model
is based upon the same underlying changes to development which
lead to expression of the disease.
In the following section, I will brieﬂy summarize zebraﬁsh
models of ADHD, schizophrenia, ASDs, and X-linked mental
retardation (XLMR).
ZEBRAFISH MODELS OF ADHD
Attention-deﬁcit/hyperactivity disorder is a common neuropsy-
chiatric disorder that is characterized by developmentally inap-
propriate inattention, hyperactivity, and impulsivity. It affects
around 3–5% of children worldwide regardless of nationality or
cultural setting (Swanson et al., 1998; Polanczyk et al., 2007). The
symptoms of ADHD persist into adulthood in about 50% of cases
and can lead to a reduction in the quality of the sufferer’s life
including impairment of academic, behavioral, and social per-
formance (Barkley et al., 2006; Schmidt and Petermann, 2009).
ADHD patients are also more likely to suffer from other psychi-
atric disorders, including depression, anxiety, and substance use
disorder (Molina and Pelham, 2003; Lesch et al., 2008; Sharp et al.,
2009). Data from drug treatments and genetic analyses have sug-
gested that alterations in DA and noradrenaline (NA; and to a
lesser extent 5-HT and glutamate) signaling most likely underlie
the symptoms of ADHD. For example, methylphenidate (MPH),
an amphetamine like compound that increases both DA and NA
levels in the prefrontal cortex (Berridge et al., 2006) can be used to
manageADHDand so has orientated research towardmonoamin-
ergic signaling. ADHD patients are thought to have a reduction
of dopaminergic signaling in the prefrontal cortex. Other brain
areas which have been connected to ADHD include the striatum
(caudate nucleus and putamen) the parietal cortex and both the
vermis and the inferior lobes of the cerebellum (Berquin et al.,
1998; Arnsten, 2007; Bush, 2010; Rubia, 2011).
Multiple DA pathway-related genes have been linked toADHD.
Association with polymorphisms in the gene encoding the DA D4
receptor (DRD4; Ebstein et al., 1996; LaHoste et al., 1996), the DA
D5 receptor (DRD5; Hawi et al., 2002), and the DA transporter
gene (DAT/SLC6A3; Cook et al., 1995) have been reported. Most
studies of DAT have focused on a 40 base-pair variable num-
ber tandem repeat (VNTR) found in the 3′ untranslated region
(UTR) of the gene (Vandenbergh et al., 1992; Curran et al., 2001;
Purper-Ouakil et al., 2005). There is also some evidence associat-
ing the DA synthesis enzyme Dopamine-beta hydroxylase (DBH)
and the disease (Comings et al., 1996). In the 5-HT pathway, the
5-HT synthesis enzymes TPH1 and TPH2 (Walitza et al., 2005;
Li et al., 2007) and the 5-HT transporter gene (SERT/SLC6A4;
Gizer et al., 2009) have all been linked toADHD formation. Recent
GWAS and candidate gene studies have also identiﬁed polymor-
phisms in genes that are involved in cell adhesion (including
ASTN2 and CDH13) and synaptogenesis (SNAP25,CTNNA2, and
KLRN ; Faraone et al., 2005; Lesch et al., 2011). Thus, as well
as being caused by direct modiﬁcation of neurotransmitter sig-
naling, ADHD may be triggered by more general alterations in
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brain formation, including cell-signaling, morphogenesis, and
migration during development.
There is currently only one study that has reported the use of
ﬁsh to directly study an ADHD-linked gene (Lange et al., 2012).
Lange et al. (2012) have studied latrophilin3.1, a zebraﬁsh homolog
of the humanADHD-susceptibility geneLATROPHILIN3. LPHN3
was identiﬁed by linkage analysis of a genetically isolated Euro-
pean population inColumbia, followed by ﬁne-mapping of several
North American and European populations (Arcos-Burgos et al.,
2010). Recent research has identiﬁed two families of endogenous
ligands for Latrophilin3, the Teneurins and the FLRTs (Fibronectin
Leucine-rich repeat transmembrane proteins; Silva et al., 2011;
O’Sullivan et al., 2012). latrophilin3.1 is one of two zebraﬁsh
homologs of human LPHN3, both of which are expressed in
differentiated neurons throughout the brain up to 6 days post
fertilization. lphn3.1 morphants show an increase in the distance
swum at 6 days, a hyperactive phenotype. This hyperactivity is
also maintained during the night suggesting a permanent increase
in locomotion compared to animals injected with a control mor-
pholino. Furthermore, lphn3.1morphants also show an increase in
the number of bursts of acceleration while swimming indicative
of motor impulsivity. Both hyperactivity and motor impulsiv-
ity can be rescued by applying the ADHD treatment drugs MPH
and atomoxetine. Acute treatment of either drug had no effect on
control-injected larval behavior at the doses used (10μMMPHor
1μMatomoxetine for 1 h), but rescuedmorphant behavior bring-
ing locomotion back to control levels. lphn3.1 morphants also
display a parallel reduction of dopaminergic cells in the posterior
tuberculum (PT), a prominent group of dopaminergic neurons in
the ventral diencephalon that controls larval locomotion (Bretaud
et al., 2004; Sallinen et al., 2009; Tay et al., 2011). Recent analy-
sis of the molecular signature and projection pattern of zebraﬁsh
PT neurons suggests they are similar to mammalian hypothala-
mic A11 DA neurons (Tay et al., 2011). Similar to A11, individual
PT DA neurons project both anteriorly and posteriorly with the
majority of projections (80%) going to the spinal cord (Ryu et al.,
2007; Tay et al., 2011). Lesion of A11 DA neurons in rat causes
a restless legs syndrome (RLS)-like hyperactivity phenotype and
comorbidity between RLS and ADHD has been observed (Cortese
et al., 2005). Thus common genes and neural circuitsmight under-
lie both diseases in mammals. Regardless of the homology of the
zebraﬁsh PTwith other species, lphn3.1 appears have a critical role
in controlling the development of dopaminergic neurons (Lange
et al., 2012), a ﬁnding which has recently been conﬁrmed in mice
(Wallis et al., 2012).
ZEBRAFISH MODELS OF SCHIZOPHRENIA
Schizophrenia is a severe psychiatric disorder whose symptoms
includemood changes (such as delusions and hallucinations), dis-
organization of thought, agitated body movements, anhedonia,
depression, speech problems, and a lack of motivation. Although
schizophrenia is thought to be caused by defects in early brain
development (Weinberger, 1995), disease symptoms often do not
appear until the second or third decade of life (typically between
16 and 30 years of age). Schizophrenia affects around 1% of the
adult population in the USA according to the National Institute of
Mental Health. Twin studies give a heritability estimate of about
81% for schizophrenia, and an environmental effect (including
variables such as diet, parenting style, and exposure to toxins or
teratogens) of around 11% (Sullivan et al., 2003). A large num-
ber of schizophrenia cases are sporadic, appearing for the ﬁrst
time in a family with no previous history of the disease (Xu
et al., 2008). Rare de novo CNVs are one mechanism that can
account for sporadic cases. In agreement with this, schizophrenia
patients carry more CNVs than the general population and also
have a higher than normal de novo mutation rate (Girard et al.,
2011, 2012).
Neurobiological studies have identiﬁed defects in the frontal
and temporal lobes of schizophrenia patients. Many schizophren-
ics also have enlarged cerebral ventricles linked to a 5–10%
reduction in gray matter volume in the absence of gliosis, sug-
gesting that loss of tissue is not caused by degeneration (Mueser
and McGurk, 2004). Both dopaminergic and glutamatergic neu-
rotransmission has been linked to the disease. For example, a
reduction of blood ﬂow in the prefrontal cortex related to DA
activity has been documented in schizophrenia patients (Mueser
and McGurk, 2004). Many genes have been connected to the sus-
ceptibility to suffer from schizophrenia. For example, genes with
particularly strong linkage to the disease include DISRUPTED IN
SCHIZOPHRENIA1 (DISC1),NEUREGULIN1,DYSTROBREVIN
BINDING PROTEIN1 (DTNBP1), KIF1, KIF17, SHANK3, and
NOTCH4 (Tarabeux et al., 2010; Girard et al., 2012). Develop-
mental processes which might be affected include genes which
affect neural proliferation, differentiation, and migration during
development or abnormal myelination in the schizophrenic brain
(Flynn et al., 2003).
Although it is not possible to study the positive symptoms of
schizophrenia such as disordered thought, delusions, and hallu-
cinations in zebraﬁsh, the basic developmental function of genes
linked to this disease can still be studied. For example, schizophre-
nia candidate genes may be important for neurogenesis, neuronal
migration, and cell fate determination (Morris, 2009). Burgess and
Granato (2007) have developed a schizophrenia endophenotype
in zebraﬁsh: prepulse inhibition (PPI). PPI is a type of sensori-
motor gaiting (a reduction of startle response that occurs when
preceded by a weak non-startling stimulus) that is impaired in
schizophrenic patients (Braff et al., 2007). Zebraﬁsh PPI is mod-
iﬁed by both apomorphine and ketamine [which affect DA and
N-methyl-D-aspartate (NMDA) signaling respectively] and thus
appears to be mediated by similar neurotransmitters as in other
animals. Five novel mutant lines with abnormal PPI responses
were also identiﬁed in the same study. Characterization of these
mutants might give novel insights into the genes and brain areas
that control behaviors linked to schizophrenia.
One of the most intensely studied schizophrenia-related genes
is DISC1, which was ﬁrst identiﬁed in a Scottish pedigree dis-
playing high incidence of depression, schizophrenia, and bipolar
disorder (Millar et al., 2000). DISC1 has subsequently been shown
to be involved in neurogenesis, neural migration, axon growth,
synaptogenesis and function, dopaminergic neuron function, and
cell–cell adhesion. Studies of disc1 in zebraﬁsh have provided
novel information about the function of this gene. De Rienzo
et al. (2011) have shown that disc1 has a critical role in both the
canonical (β-catenin-mediated) and non-canonicalWnt signaling
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pathways during embryonic development. Furthermore, different
humanized forms of disc1 have been shown to activate dif-
ferent signaling pathways in zebraﬁsh. For example, Ala38Val,
Arg264Gln, and Leu607Phe disc1 variants interact with canoni-
cal Wnt signaling, whereas a Ser704Cys variant modiﬁes neuronal
migration via the cytoskeletal genes nde1 and dixdc1 (Singh et al.,
2011). disc1 has also been shown to control oligodendrocyte pro-
liferation, a phenotype that can also be generated by inhibiting
the schizophrenia-susceptibility genes neuregulin1 and its receptor
erbb4 (Wood et al., 2009).
There have been several studies that have characterized
schizophrenia-related genes in zebraﬁsh. For example, the con-
nection between Akt signaling, dopaminergic neurotransmission,
and schizophrenia has been investigated. Cheng et al. (2013) have
used zebraﬁsh to study rgs4, a regulator of G-protein signaling
family that is expressed in the developing nervous system. Loss
of gene function causes both neurite outgrowth defects in the
hindbrain and spinal cord and a reduction of motility. Activa-
tion of Akt signaling can rescue the outgrowth phenotype in the
spinal cord but not hindbrain, indicating that Akt signaling is
required for some rgs4-mediated axon formation (Cheng et al.,
2013). Souza et al. (2011) have further examined the connec-
tion between Akt signaling and dopaminergic neurotransmission
in the developing brain. Since alterations in Akt signaling have
also been linked to schizophrenia, this strengthens the suggestion
that altered dopaminergic signaling during development might
underlie the disease. Other human disease-causing genes have
been studied as well. Knock-down of the synaptically expressed
schizophrenia-susceptibility gene kinesin17 (kif17) causes a severe
phenotype in zebraﬁsh embryos including stunted development
and a curly tail phenotype suggesting that kif17 is active during
embryonic development (Tarabeux et al., 2010). Finally, treat-
ment of zebraﬁsh with the NMDA receptor antagonist MK-801
causes several behavioral alterations including changes to social
interaction, hyperactivity, and amnesia, which have been inter-
preted as being schizophreniform (schizophrenia-like; Chen et al.,
2010; Seibt et al., 2010, 2011; Echevarria et al., 2011) and are
similar to the behavioral changes elicited by these psychotics in
rodents.
In summary, although it is not possible to model some of the
more complex psychological symptoms of schizophrenia in ﬁsh,
several recent studies have given insights into some of the basic
processes underlying this disease.
ZEBRAFISH MODELS OF AUTISM SPECTRUM DISORDER
Autism spectrum disorder encompasses a range of psychiatric
diseases including autism (the severest form of ASD), Rett’s syn-
drome, and Asperger’s syndrome. The symptoms of ASD are
highly variable between patients making it difﬁcult uncover the
genetic and neurobiological changes that underlie these disorders.
Broadly speaking, the main symptoms of ASD include alterations
in social behavior, repetitive behavior, and language development
that appear before 3 years of age (Lord et al., 2000). There is a
heritability estimate of between 70 and 80% for ASD (Bailey et al.,
2005; Rosenberg et al., 2009). However, the number of people
thought to suffer from ASD is increasing over time which might
be due to a shift in the diagnostic criteria used (Lord, 2010).
Although it is not possible to study complex behaviors such as
language development in ﬁsh, a few recent studies have provided
information about the functionofASD-linked genes duringneural
development.
Both common and rare (de novo) genetic variants, acting in
combination with environmental inﬂuences, are associated with
ASD. ASD-linked polymorphisms are predominantly found in
genes that regulate synapse development, cell proliferation, neural
migration, and neural projection. Raremutations seem to account
for around 10% of cases of ASD (Geschwind, 2008). It has been
suggested that there may be a different genetic basis for simplex
families (where only one child is affected and rare mutations are
common) andmultiplex families (where multiple genetic variants
lead to ASD expression in several family members; Geschwind,
2008). For example, there is a higher frequency of CNVs in ASD
families with only one affected child compared to those with two
or more ASD children (Toro et al., 2010). Interestingly, there is
also some data suggesting that rare and common variants interact
to trigger ASD symptoms (Ben-David and Shifman, 2012). Genes
whichhavebeen linked toASD include theFragileXgeneFRAGILE
X MENTAL RETARDATION 1 (FMR1), the GABAA β 3 subunit
gene GABRB3 as well as SHANK3, TSC1, NEUROLIGIN3 and
NEUROLIGIN4, PTEN and CNTNAP2 (Cook and Scherer, 2008;
Geschwind, 2008, 2011; Lord, 2010) amongst others. The neuro-
biology of ASD is not well understood, but most likely includes
brain areas which are needed for the control of social behavior and
language. For example, altered connections between the frontal
lobe (the orbitofrontal cortex) and temporal lobe (including the
superior temporal gyrus and temporal polar cortex) may mediate
some symptoms of the disease (Geschwind, 2011). Other impor-
tant brain areas include the cerebellum, brainstem, and limbic
areas including the hippocampus, amygdala, septal nuclei, and the
anterior cingulate cortex (Lord et al., 2000). Finally, autism has
also been related to megalencephaly, an overall increase in brain
size in some patients.
Since the symptoms of ASD ﬁrst occur during neural devel-
opment it is possible to study the early function of ASD-related
genes in this species (Tropepe and Sive, 2003). There are only a
few research articles reporting the use of zebraﬁsh in this type
of research. In humans, a CNV at 16p11.2 has been associated
with susceptibility to suffer from several disorders, including ASD,
epilepsy, autism, and schizophrenia. The 16p11.2 CNV has been
studied in zebraﬁsh by two groups (Blaker-Lee et al., 2012; Golzio
et al., 2012). In a landmark study, Golzio et al. (2012) analyzed
24 of the genes contained within this CNV and identiﬁed one,
KCDT13, as most likely being causative for the disease. Over-
expression of kcdt13 (by mRNA injection) led to microcephaly,
whereas gene-speciﬁcmorpholinoknock-downcaused an increase
in head size, likely due to alteration of the cell cycle in both
cases. This study provides a neat demonstration of the use of
zebraﬁsh to identify disease-causing variants within large genomic
regions. Gauthier et al. (2010) have used morpholinos to knock-
down SHANK3, a gene linked to schizophrenia andASD in human
patients. shank3 morphant zebraﬁsh show decreased swimming
after being touched, a phenotype which can be rescued with a
wild-type (but not a mutant) version of the corresponding rat
gene. Therefore, this study validated alterations to shank3 as being
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important in the control of behavior, with potential implications
for both schizophrenia and ASD.
ZEBRAFISH MODELS OF MENTAL RETARDATION
Mental retardation constitutes a signiﬁcant impairment of cogni-
tive function that can be symptomatic of a number of underlying
neural defects. In this review, I have chosen to focus onXLMR(also
calledFragileX syndrome, FXS) a common inherited formofmen-
tal retardation which affects around 1 in 4000 people. However,
zebraﬁsh have also been used to examine other types of men-
tal retardation (for recent studies, refer to Komoike et al., 2010;
Song et al., 2010; Brockschmidt et al., 2011; Friedrich et al., 2012;
Veleri et al., 2012; Aspatwar et al., 2013). The symptoms of FXS
include mental retardation, epilepsy, autistic-like behavior, atten-
tion deﬁcits, macroorchidism, andmild craniofacial defects which
have been linked to the maturation of dendritic spines during
development.
Similar to schizophrenia and ASD, it is likely to be impossible
to model the cognitive symptoms of mental retardation in ﬁsh.
However, several zebraﬁsh groups have analyzed XLMR-linked
genes and provided information about their role during devel-
opment. For example, XLMR is most often caused by mutations
in the FMR1 gene, which contains a variable CGG trinucleotide
repeat sequence in its 5′ UTR (Verkerk et al., 1991). Once this
repeat passes 200 copies, the gene becomes hypermethylated and
loss of function occurs. Interestingly, this methylation appears to
be mediated by a microRNA which is present in the 3′ UTR of
FMR1, an observation which has been experimentally conﬁrmed
in zebraﬁsh (Lin et al., 2006). Injection of a construct targeting
the anti-fmr1 miRNA causes abnormal neural morphology and
an increase in the size of the head (Lin et al., 2006).
Studies of the zebraﬁsh homolog of the FMR1 gene have given
equivocal results. Intriguingly, different phenotypeswere observed
when comparing morpholino-mediated knock-down and a sta-
ble fmr1 mutant line. Morphant larvae show craniofacial defects,
hydrocephaly, and pericardial edema as well as abnormal branch-
ing of the trigeminal ganglion and lateral longitudinal fasciculus
(Tucker et al., 2006). However, in contrast to this, fmr1 mutant
larvae are adult viable and show no detectable morphological dif-
ferences (Den Broeder et al., 2009). Thus, it is clear that further
studies are needed in order to fully understand the function of this
gene during development. Qi et al. (2010) studied the XLMR gene
phf8 during zebraﬁsh development. phf8 is amono-methyl histone
H4 lysine 20 demethylase that is expressed in the developing head
and jaw of zebraﬁsh at 1 day. Loss of gene function causes severe
disruption to development of these structures, most likely caused
by increases in apoptosis (Qi et al., 2010). Histone methylation
has also been linked to XLMR in a study of the smcx/jarid1c gene,
a H3K4 demethylase (Iwase et al., 2007). Loss of smcx function
during development leads to increased cell death and a smaller
brain as well as a reduced number of dendrites. Together, both of
these studies suggest that epigenetic events might play an impor-
tant role in the etiology of XLMR. Another XLMR-linked gene,
rbmx, shows strong expression in the anterior developing embryo
including the brain (Tsend-Ayush et al., 2005). Knock-down of
rmbx leads to a reduction in body size, pericardial edema, hydro-
cephaly, and reduced motility (Tsend-Ayush et al., 2005). Finally,
the non-syndromic mental retardation genes il1rapl1a, il1rapl1b,
and il1rapl2 (zebraﬁsh homologs of human IL1RAPL, which is
located on the X chromosome) are widely expressed through-
out the brain. Knock-down of one of the homologs, ilrapl1b,
inhibits presynaptic differentiation during development (Yoshida
and Mishina, 2008).
There are several learning and choice discrimination tests that
have been developed for adult zebraﬁsh which could be used to
test possible cognitive functions of mental retardation-associated
genes. For example, Brennan and colleagues have developed a
3-choice serial reaction time task (3CSRTT) that can be used to
measure impulsivity (Parker et al., 2012). The 3CSRTT is mea-
sured in a tank that has a green light-emitting diode (LED) on
one side and three yellow LEDs in separate compartments on the
other. Following illumination of the green LED, adult zebraﬁsh
are taught to only enter the compartment where the yellow LED is
switched on. The correct execution of this behavior is reinforced
with a food reward. Following a training period in which the ﬁsh
learns to associate the yellow light with a reward the 3CSRTT
can begin. The green stimulus LED is ﬁrst activated and is then
followed by a 10-s intertrial interval (ITI). Following this pause,
one of the yellow LEDs is lit and the ﬁsh is rewarded with food
upon entering the correct compartment. However, entry into any
compartment before the end of the ITI, perhaps indicative of
impulsivity, will result in a punishment (a 10-s time-out with no
food). Entry into an incorrect compartment on the other side (i.e.,
one in which the yellow LED is not illuminated) will also trigger
the punishment. Other tests of learning and memory, including
associative-, avoidance-, and spatial memory have also been estab-
lished (reviewed in Norton and Bally-Cuif, 2010). Although these
tests appear to be promising in to study zebraﬁsh cognition, they
havemostly only been tested on wild-type ﬁsh and so need further
validation (for example, in ﬁsh lacking the function of a disease-
linked gene) before they can be proposed as retardation-linked
phenotypes.
FUTURE DIRECTIONS FOR RESEARCH INTO PSYCHIATRIC
DISORDERS USING ZEBRAFISH
The functions of genes linked to psychiatric disorders are still rel-
atively understudied in zebraﬁsh. However, the power of zebraﬁsh
as a model organism to study neural development and behavior
suggest that there are several areas in which the zebraﬁsh has the
potential to provide more information related to these diseases, as
discussed below.
ENVIRONMENTAL CONTRIBUTIONS TO DISEASE ONSET
Since zebraﬁsh embryos develop outside of their mother, it is
easy to manipulate their environment and so carry out G × E
studies. Although it is not possible to model adverse psychosocial
environments (such as parenting styles) in ﬁsh, other environmen-
tal factors including exposure to alcohol or nicotine could easily
be studied. Ethanol exposure during development causes a range
of phenotypes depending on the timing and concentration used,
making it difﬁcult to get an overview of themechanismunderlying
the action of this drug, or how it might relate to alcohol-related
changes to behavior inhumans. At concentrations greater than2%,
ethanol causes gross body abnormalities including cardiac edema,
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cyclopia, and dysmorphia (Blader and Strahle, 1998; Sylvain
et al., 2010). Lower concentrations trigger behavioral alterations
in the absence of obvious morphological changes. For example,
transient exposure to ethanol can lead to either locomotor hyper-
activity (Tal et al., 2012), a reduction of swimming coupled to
defects in secondary motorneuron development and synaptogen-
esis (Sylvain et al., 2010, 2011) or reduced shoaling in adult ﬁsh
(Fernandes and Gerlai, 2009; Buske and Gerlai, 2011). Embryos
which are treated with nicotine during development tend to be
smaller, with a permanent delay and disruption of secondary
motorneuron development (Svoboda et al., 2002; Menelaou and
Svoboda, 2009). Nicotine also causes a transient increase in
swimming speed, followed by a long-lasting reduction in both
startle response and swimming speed, a phenotype which is most
likely mediated via activation of nAChRs (Svoboda et al., 2002;
Eddins et al., 2010).
Oneof thedifﬁculties of designingG×E studies, highlightedby
the examples related to ethanol and nicotine, will be to mimic the
situation in nature as closely as possible. Although environmental
alterationsmaymodify the severity of an obvious pre-existing phe-
notype, in some cases environmental inﬂuenceswould be expected
to trigger disease-related symptoms in a genotype that initially
looks normal. One way to address this issue would be to develop
a zebraﬁsh transgenic line that contains a humanized form of
the disease-risk gene and then subject embryos to different envi-
ronmental conditions (such as varying concentrations of ethanol
or nicotine exposure) before measuring behavior. Although such
an approach is not more technically difﬁcult than starting with
a measurable behavioral change, it would require researchers to
have more conﬁdence when developing the assay.
SCREENING FOR NOVEL DRUGS
Zebraﬁsh are a good model system for pharmacological stud-
ies, since compounds can be diluted in the embryo medium,
and larvae are transparent meaning that internal organs can be
visualized throughout development (Peterson et al., 2000). Fur-
thermore, larvae are small, easy to generate in large numbers and
easy to manipulate making them ideal for high-throughput work.
However, since screens that use behavior as a read-out are difﬁ-
cult to design and implement efﬁciently (particularly if focusing
on complex behaviors other than locomotion), it might be eas-
ier to carry out an initial pre-screen of a disease endophenotype.
For example, zebraﬁsh lacking the function of the ADHD-linked
gene lphn3.1 show a reduction and displacement of dopaminer-
gic neurons in the PT of the diencephalon (Lange et al., 2012).
Pre-screening libraries for compounds which can rescue this phe-
notype might speed up the screening process, with a subset of
promising drugs then being re-tested to assess their behavioral
function.
Two studies have combined analysis of underlying chemical
structure and high-throughput screening of chemical libraries to
look for alterations to the photomotor response, an embryonic
motor response to a series of light ﬂashes (Kokel et al., 2010; Lag-
gner et al., 2012). This assay can be performed in a 96-well plate,
and can be scaled up to analyze around 5000 novel chemicals every
day. Rihel et al. (2010) uncovered the effect of drugs on loco-
motor activity across different sleep/wake cycles, providing novel
information about neuroactive drugs which can affect behav-
ior. In this study, chemicals were categorized according to their
“behavioral ﬁngerprint,” a combination of their chemical struc-
ture and their ability tomodify aspects of behavior, thus permitting
prediction of the function of novel chemicals.
A screen for novel anti-epileptic drugs was conducted in 2-day-
old zebraﬁsh embryos by Baxendale et al. (2012). Although not
a developmental psychiatric disorder, this work further demon-
strates the utility of zebraﬁsh for drug identiﬁcation. Exposure
of embryos to the convulsant pentylenetetrazole (PTZ) upregu-
lates expression of the immediate-early gene fos in the brain. The
level of fos expression (assayed by in situ hybridization) was then
used to screen a bioactive small-molecule library with a hit rate
of 2.3% for anti-convulsive drugs (Baxendale et al., 2012). Using
a similar approach, Baraban (2007) screened for novel zebraﬁsh
mutant lines which are resistant to the seizure-inducing proper-
ties of PTZ at 7 days post fertilization. Six novel mutant lines were
identiﬁed, raising the possibility of uncovering novel genes with a
seizure-protective function. The effects of the stimulants ethanol,
amphetamine, and cocaine on larval swimming behavior have also
been reported (Irons et al., 2010). Whilst not high-throughput,
this study demonstrates the ease of screening motor behavior in
96-well plates, meaning that this paradigm could potentially be
used to look at hyperactivity or startle, endophenotypes related to
psychiatric disorders.
Although zebraﬁsh constitute a power model system for drug
screens, further experiments will be required before data can be
translated to human patients. In a ﬁrst step, the results will need
to be veriﬁed in a second animal model – most likely a knock-
out mouse harboring a similar genetic lesion. Analysis of further
disease models with and without drug treatment will provide
information about selectivity of the chemical compound for one
or more signaling pathways. A drug with a similar proﬁle in both
ﬁsh and mouse will represent a very promising target for clinical
trials as long as no toxic effects are detected.
CONCLUSION
A full understanding of the basis of psychiatric disorders requires
the characterization of complex behaviors such as thought, feel-
ing, and emotion, most likely through translational experiments
in a combination of model organisms such as zebraﬁsh and
rodents. However, the suitability of zebraﬁsh for developmental
studies, and the genetic tools which are available to manipulate
them suggest that the early development function of psychiatric
disorder-linked genes can be studied in thismodel organism. Stud-
ies of genes linked to ADHD, schizophrenia, ASD, and mental
retardation that have been performed in zebraﬁsh have already
demonstrated the validity of this approach. I look forward to
future developments in this exciting ﬁeld.
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